Small Cell Lung Cancer (SCLC)

>

Latest News

Orphan Drug Designation Granted to 225Ac-SSO110 for SCLC
Orphan Drug Designation Granted to 225Ac-SSO110 for SCLC

February 8th 2025

Following promising results from a trial investigating the effects of 225Ac-SSO110 on Balb/c nude mice injected with the xenograft model of SCLC, IND clearance was granted by the FDA.

Support for the recommendation is based on phase 3 ADRIATIC trial results showing a 27% reduction in the risk of death with durvalumab vs placebo.
CHMP Recommends EU Approval for Durvalumab in Limited-Stage SCLC

February 4th 2025

ZL-1310 Receives Orphan Drug Designation in Small Cell Lung Cancer
ZL-1310 Receives Orphan Drug Designation in Small Cell Lung Cancer

January 23rd 2025

Sacituzumab Govitecan Earns Breakthrough Therapy Designation in ES-SCLC
Sacituzumab Govitecan Earns Breakthrough Therapy Designation in ES-SCLC

December 18th 2024

FDA OKs Durvalumab in Limited-Stage SCLC
FDA OKs Durvalumab in Limited-Stage SCLC

December 4th 2024